Suda Pharmaceuticals Ltd Операционная прибыль
Что обозначает Операционная прибыль в Suda Pharmaceuticals Ltd?
Операционная прибыль Suda Pharmaceuticals Ltd является -454.92%
Какое определение для Операционная прибыль?
Показатель относительной доходности компании - это отношение операционной прибыли, деленной на чистую выручку и выраженной в процентах.
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
Операционная прибыль компаний в Health Care сектор на ASX по сравнению с Suda Pharmaceuticals Ltd
Что делает Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Компании с операционная прибыль похож на Suda Pharmaceuticals Ltd
- Bicycle Therapeutics plc имеет Операционная прибыль из -463.51%
- Equus Total Return Inc имеет Операционная прибыль из -460.12%
- Canopy Rivers имеет Операционная прибыль из -458.60%
- DXStorm.com имеет Операционная прибыль из -458.33%
- TALI Digital имеет Операционная прибыль из -455.26%
- Eiger BioPharmaceuticals Inc имеет Операционная прибыль из -455.12%
- Suda Pharmaceuticals Ltd имеет Операционная прибыль из -454.92%
- Strata-X имеет Операционная прибыль из -454.75%
- Strata-X имеет Операционная прибыль из -454.75%
- Real имеет Операционная прибыль из -454.75%
- Relief Therapeutics AG имеет Операционная прибыль из -453.24%
- PharmaCielo имеет Операционная прибыль из -451.23%
- Sensyne Health plc имеет Операционная прибыль из -450.76%